HTX Ascends in Global Rankings: Solidifying Web3 Leadership Grounded in User Trust
SINGAPORE, June 10, 2025 (GLOBE NEWSWIRE) -- HTX, a leading global cryptocurrency exchange, is proud to announce its significant climb in comprehensive rankings across multiple authoritative crypto data platforms. This remarkable upward trajectory underscores HTX's burgeoning recognition and reinforces its position as a trusted leader among users worldwide.
HTX continues to earn global user trust through its unwavering commitment to excellence in security, trading depth, user experience, and robust ecosystem development, firmly establishing itself as a pivotal force in the Web3 space.
HTX's Global Influence Soars as It Climbs Authoritative Rankings
CoinGecko: HTX's ranking on CoinGecko, a globally authoritative crypto data platform, has dramatically risen from 13th to 7th place. This achievement not only reflects a notable improvement in the exchange's overall strength but also underscores its outstanding performance in global user activity, security, and transparency. As a benchmark for crypto asset security ratings, CoinGecko's ranking further affirms HTX's continued efforts to optimize its security systems and drive technological innovation.
Source: CoinGecko
CoinMarketCap (CMC): HTX has secured the 9th spot on CMC, jumping from 15th on the world's most visited Web3 platform. This significant milestone strengthens HTX's status as a top-tier exchange in the minds of global Web3 users, reflecting its rising influence, growing user trust, and expanding international presence in the crypto space.
Source: CoinMarketCap
DefiLlama: HTX maintains its 6th position on DefiLlama, a key platform for North America. This consistent ranking showcases HTX's active presence and solid market share in the region, supported by its dedication to global regulatory compliance and its commitment to delivering a secure, transparent trading environment to users.
Source: DefiLlama
Kaiko: HTX has advanced from 10th to 8th position on Kaiko, a respected platform among North American high-end crypto users, and received an 'AA' rating. Kaiko evaluates the comprehensive performance of over 100 mainstream trading platforms worldwide across six key dimensions: governance, liquidity, technology, business capabilities, security, and data quality. This accolade highlights HTX's excellence in business and technological capabilities, as well as its strong security measures, emphasizing its competitive edge in the high-end market.
Source: Kaiko
CryptoRank: HTX proudly holds the 3rd position on CryptoRank, a popular platform in the CIS region. This ranking showcases HTX's deep market penetration and growing brand strength, reinforcing its status as a trusted international trading platform for CIS users.
Source: CryptoRank
HTX Builds Global Trust with a User-First Approach
HTX's consistent ascent in global rankings underscores its steadfast dedication to user asset security, innovative product development, strategic global expansion, and robust service infrastructure. Guided by its core philosophy of 'Putting Users First and Ensuring the Security of User Assets,' HTX continually refines its security, enhances the trading experience, and delivers diverse, innovative products worldwide. This unwavering commitment has earned HTX widespread global recognition, solidifying its position as a leader in the crypto market.
According to official data, HTX has published its asset reserve records for 32 consecutive months, reaffirming its position as one of the most transparent platforms in the industry. Over the past three months, it has seen a remarkable increase in total asset balances. Notably, USDT holdings have surged from approximately 665 million to 1.15 billion, marking a month-over-month growth of over 30% in May. This reflects HTX's commitment to strengthening asset reserves and enhancing user asset protection.
Moving forward, HTX will continue to prioritize user needs, driving continuous improvements in platform security, trading depth, and service quality. Our vision is clear: to establish HTX as the world's foremost comprehensive Web3 trading platform.
About HTX
Founded in 2013, HTX has evolved from a virtual asset exchange into a comprehensive ecosystem of blockchain businesses that span digital asset trading, financial derivatives, research, investments, incubation, and other businesses.
As a world-leading gateway to Web3, HTX harbors global capabilities that enable it to provide users with safe and reliable services. Adhering to the growth strategy of 'Global Expansion, Thriving Ecosystem, Wealth Effect, Security & Compliance,' HTX is dedicated to providing quality services and values to virtual asset enthusiasts worldwide.
To learn more about HTX, please visit HTX Square or https://www.htx.com/, and follow HTX on X, Telegram, and Discord.
For further inquiries, please contact Ruder Finn Asia, [email protected]
Disclaimer: This is a paid post and is provided by HTX. The statements, views, and opinions expressed in this content are solely those of the content provider and do not necessarily reflect the views of this media platform or its publisher. We do not endorse, verify, or guarantee the accuracy, completeness, or reliability of any information presented. We do not guarantee any claims, statements, or promises made in this article. This content is for informational purposes only and should not be considered financial, investment, or trading advice. Investing in crypto and mining-related opportunities involves significant risks, including the potential loss of capital. It is possible to lose all your capital. These products may not be suitable for everyone, and you should ensure that you understand the risks involved. Seek independent advice if necessary. Speculate only with funds that you can afford to lose. Readers are strongly encouraged to conduct their own research and consult with a qualified financial advisor before making any investment decisions. However, due to the inherently speculative nature of the blockchain sector—including cryptocurrency, NFTs, and mining—complete accuracy cannot always be guaranteed. Neither the media platform nor the publisher shall be held responsible for any fraudulent activities, misrepresentations, or financial losses arising from the content of this press release. In the event of any legal claims or charges against this article, we accept no liability or responsibility. Globenewswire does not endorse any content on this page.
Legal Disclaimer: This media platform provides the content of this article on an 'as-is' basis, without any warranties or representations of any kind, express or implied. We assume no responsibility for any inaccuracies, errors, or omissions. We do not assume any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information presented herein. Any concerns, complaints, or copyright issues related to this article should be directed to the content provider mentioned above.
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/71a4ab6f-87c8-4abf-9397-bd1c96dd2c38
https://www.globenewswire.com/NewsRoom/AttachmentNg/3de1e080-041d-47b8-988c-6a2f7de5e6ff
https://www.globenewswire.com/NewsRoom/AttachmentNg/02121c54-4403-4427-929e-97859c679178
https://www.globenewswire.com/NewsRoom/AttachmentNg/8e4d98d6-08d1-43ec-9e9b-6d8ca2a116a1
https://www.globenewswire.com/NewsRoom/AttachmentNg/4bd5342d-4579-47d8-94dc-e30436a46ff0
https://www.globenewswire.com/NewsRoom/AttachmentNg/61261585-ac35-4b5f-bb7e-13ca1232154c
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
25 minutes ago
- Bloomberg
Odd Lots: The Secretive Chinese Chip Giant That Could Be Nvidia's Biggest Threat
Right now, Nvidia stock is back near its all-time highs, thanks to seemingly unquenchable demand for its AI chips. When it comes to profiting off of this boom, Nvidia's lead and lock-in looks almost unassailable. But there is one particular company that is clearly on the mind of CEO Jensen Huang, and that is Huawei. On this episode, we speak with Washington Post reporter Eva Dou, the author of the new book House of Huawei: The Secret History of China's Most Powerful Company. Her book explains how the historical development of Huawei is basically synonymous with the rise of modern China, having started early on in Shenzhen, when that was one of the few parts of the country where capitalism and free enterprise were allowed to take root. She discusses what the company does, how it became so strong, its links to the Chinese government, and how it emerged as a possible rival to Nvidia.
Yahoo
36 minutes ago
- Yahoo
Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
- Exclusive collaboration and license agreement for povetacicept in these countries - - Ono will leverage its deep expertise in clinical development and commercialization for chronic kidney disease in Japan and South Korea to accelerate advancement of povetacicept for patients with IgA nephropathy and primary membranous nephropathy - BOSTON & OSAKA, Japan, June 23, 2025--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Ono Pharmaceutical Co., Ltd. (OTCMKTS: OPHLY) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex's povetacicept in Japan and South Korea. Povetacicept is a recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines with best-in-class potential being studied for the treatment of immunoglobulin A nephropathy (IgAN), primary membranous nephropathy (pMN) and other B cell-mediated diseases. Under the terms of the agreement, Vertex will receive an upfront payment, as well as certain regulatory and commercial milestone payments and tiered royalties. Ono will utilize its extensive development expertise to help advance Vertex's clinical trials for povetacicept and will be responsible for obtaining marketing authorizations in Japan and South Korea. Following approval, Ono will be solely responsible for commercializing povetacicept in these regions. The agreement includes povetacicept for both IgAN and pMN, with the potential to add other indications. "Ono is a proven leader in Japan and South Korea, bringing established local relationships, infrastructure and nephrology expertise that make them a perfect partner for Vertex as we look to deliver povetacicept to the thousands of potential patients in these countries," said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. "We are very pleased to partner with Ono and look forward to close collaboration as we continue to advance this potentially best-in-class treatment for IgAN, pMN and other serious B cell-mediated diseases." "Vertex has a strong track record of developing innovative therapies for serious diseases. Through this strategic partnership, we can strengthen our late-stage pipeline in the immunology field, which is a key focus area for Ono," said Toichi Takino, Representative Director, President and Chief Operating Officer of Ono. "We look forward to collaborating with Vertex to provide this new therapeutic option for patients with IgAN and other autoimmune diseases in Japan and South Korea, and to maximize the value of this treatment." About Povetacicept Povetacicept is a recombinant fusion protein therapeutic and a dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, which play key roles in pathogenesis of multiple autoimmune diseases via their roles in the activation, differentiation and/or survival of B cells, T cells and innate immune cells. Based upon an engineered TACI (transmembrane activator and calcium modulator ligand interactor) domain, povetacicept has higher binding affinity and greater potency in preclinical studies versus other inhibitors of BAFF and/or APRIL alone and has demonstrated potential best-in-class efficacy in a clinical trial in patients with IgA nephropathy and primary membranous nephropathy. Povetacicept is also in development for multiple serious B cell-mediated diseases including other autoimmune kidney diseases and autoimmune cytopenias. About IgA Nephropathy (IgAN) IgAN is a serious, progressive, life-threatening, B cell-mediated chronic kidney disease that is the most common cause of primary (idiopathic) glomerulonephritis, affecting approximately 300,000 people in the United States and Europe. It is estimated that there are approximately 33,000 diagnosed patients in Japan. IgAN results from deposition of circulating immune complexes consisting of immunoglobulins and galactose-deficient immunoglobulin A (Gd-IgA1) in the renal glomerular mesangium, triggering kidney injury and fibrosis. Up to 72% of adult IgAN patients progress to end-stage renal disease within 20 years. There are no approved therapies that specifically target the underlying cause of IgAN. About Primary Membranous Nephropathy (pMN) Primary membranous nephropathy is a serious, progressive, life-threatening B cell-mediated chronic kidney disease affecting people worldwide, with approximately 150,000 people diagnosed in the U.S. and Europe. It is estimated that there are approximately 6,000 diagnosed patients with pMN in Japan. pMN is a rare glomerular disease that occurs when the body generates an abnormal immune response, including autoantibodies, against proteins that are part of the kidney. Autoantibodies trigger damage and inflammation, especially within the glomeruli (the parts of the kidney that filter blood), impairing the kidneys' ability to properly filter waste and fluid, eventually causing progressive loss of kidney function. There are no approved therapies that specifically target the underlying cause of pMN. About RAINIER RAINIER is a global Phase 3 pivotal trial of povetacicept 80 mg vs. placebo on top of standard of care in approximately 480 people with IgAN. The study is designed to have a pre-planned interim analysis evaluating urine protein to creatinine ratio (UPCR) for the povetacicept arm versus placebo after a certain number of patients reach 36 weeks of treatment. If positive, the interim analysis may serve as the basis for Vertex to seek accelerated approval in the U.S. Final analysis will occur at two years of treatment, with a primary endpoint of total eGFR slope through Week 104. The Phase 3 clinical trial is underway in multiple regions, including the U.S., EU and Asia. Specifically, Japanese and South Korean regulatory authorities have approved the Clinical Trial Application (CTA) for RAINIER, where the Phase 3 trial is underway. About RUBY-3 RUBY-3 is an ongoing, multiple ascending dose, multi-cohort, open label, Phase 1/2 basket study of povetacicept in autoimmune glomerulonephritis, including IgAN, primary membranous nephropathy, lupus nephritis and ANCA-associated vasculitis with glomerulonephritis where povetacicept is being administered subcutaneously for up to 104 weeks. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune's 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit or follow us on LinkedIn, Facebook, Instagram, YouTube and X. About Ono Pharmaceutical Co., Ltd Ono Pharmaceutical Co., Ltd. delivers innovative therapies for patients worldwide. Upholding its philosophy of "Dedicated to the Fight against Disease and Pain," Ono targets areas with unmet medical needs including oncology, immunology, and neurology, and fosters partnerships with academic and biotech organizations to accelerate drug discovery. Through its affiliate, Deciphera Pharmaceuticals, Ono is accelerating clinical development and commercial operations in the US and Europe to drive global business expansion and further its commitment to patient care. For more information, please visit the company's website at Vertex Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements by Reshma Kewalramani M.D., and Toichi Takino, in this press release, and statements about the terms of and expectations for Vertex's collaboration with Ono, statements about potential benefits and results that may be achieved through the collaboration, statements regarding the future activities of the parties pursuant to the collaboration, including Ono's help to advance clinical trials and Ono's responsibility to obtain marketing authorizations in Japan and South Korea and to commercialize povetacicept in the regions, statements regarding upfront and milestone payments, and potential royalties on future products, and statements about Vertex's plans and expectations for the RAINIER and RUBY-3 clinical trials and potential plans to seek accelerated approval in the U.S. based on interim analysis from the RAINIER trial. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that the anticipated benefits and potential of the collaboration between Vertex and Ono may not be achieved on the anticipated timeline, or at all, that data may not support further development of the therapies subject to the collaboration due to safety, efficacy, or other reasons, and other risks listed under the heading "Risk Factors" in Vertex's annual report filed with the Securities and Exchange Commission (SEC) and available through Vertex's website at and on the SEC's website at You should not place undue reliance on these statements. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available. (VRTX-GEN) Ono Forward-Looking Statements In this press release, statements made with respect to current plans, estimates, strategies and beliefs, and other statements that are not historical facts are forward-looking statements about the future performance of the company. These statements are based on current assumptions and beliefs in light of the information currently available and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in the business environment in the pharmaceutical market and amendments to relevant laws and regulations, (ii) disruptions to product supply due to stagnation or delays in production caused by natural disasters, fires, etc., (iii) the possibility that sales activities for new and existing products may not achieve the expected results, (iv) the emergence of new side effects in post-marketing drugs, and (v) infringements of intellectual property rights by third parties. Information about pharmaceutical products included in this press release is not intended to constitute an advertisement or medical advice. View source version on Contacts Vertex Pharmaceuticals Incorporated Investors: InvestorInfo@ Media: mediainfo@ orInternational: +44 20 3204 5275orU.S.: 617-341-6992orHeather Nichols: +1 617-839-3607Ono Pharmaceutical Co., Ltd. Corporate Communications public_relations@
Yahoo
an hour ago
- Yahoo
Metaplanet Buys 1,111 Bitcoin for $117M, Pushes Total Holdings to Over 11K BTC
Metaplanet, the Tokyo-listed hotel firm known for its bitcoin BTC acquisition strategy, has acquired 1,111 bitcoin for $117 million. The firm bought bitcoin at an average price of about $105681 per BTC. The crypto markets fell during the weekend after the U.S. bombed several nuclear sites in Iran, pushing bitcoin to lows of $98,000. Bitcoin has recovered from the weekend fall and is now trading over $101,000 at the time of writing. The latest acquisition pushes Metaplanet's total BTC stash to 11,111 bitcoin, worth over $1.1 billion, with an average buying price of $95, in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
